Cargando…
Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell h...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813211/ https://www.ncbi.nlm.nih.gov/pubmed/36619621 http://dx.doi.org/10.3389/fmed.2022.1070828 |
_version_ | 1784863883720130560 |
---|---|
author | Cronin, Christopher McLaughlin, Ronan Lane, Louise Brett, Francesca M. Jansen, Michael Bermingham, Niamh Wyse, Gerald Grogan, Liam Morris, Patrick G. O’Reilly, Seamus |
author_facet | Cronin, Christopher McLaughlin, Ronan Lane, Louise Brett, Francesca M. Jansen, Michael Bermingham, Niamh Wyse, Gerald Grogan, Liam Morris, Patrick G. O’Reilly, Seamus |
author_sort | Cronin, Christopher |
collection | PubMed |
description | BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell histiocytosis. This series describes three patients from two neurosurgical centers in Ireland with BRAF V600E-mutated CNS tumors. The study participants include a 19-year-old male patient with ganglioglioma with anaplastic features, a 21-year-old male patient with CNS involvement of RDD, and a 28-year-old female patient with ganglioglioma with anaplastic features. Two patients received radiation with concurrent temozolomide before BRAF-targeted therapy. This case series describes clinical and radiological responses to BRAF-targeted therapy in BRAF V600E-mutated gliomas across multiple tumor grades and is only the second published report of response to targeted therapy in BRAF-mutated RDD. The durability of disease control with BRAF-targeted therapy was generally superior to that achieved with chemoradiation; one patient has experienced ongoing disease control for 5 years. The reported case of treatment response in BRAF-mutated RDD supports the strategy of genotyping and utilization of targeted therapy in this rare disease. The optimal sequencing of BRAF-targeted therapy in BRAF-mutated gliomas/glioneuronal tumors remains unclear, and further prospective studies are required to guide the use of genome-matched therapy in this patient population. |
format | Online Article Text |
id | pubmed-9813211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98132112023-01-06 Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease Cronin, Christopher McLaughlin, Ronan Lane, Louise Brett, Francesca M. Jansen, Michael Bermingham, Niamh Wyse, Gerald Grogan, Liam Morris, Patrick G. O’Reilly, Seamus Front Med (Lausanne) Medicine BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell histiocytosis. This series describes three patients from two neurosurgical centers in Ireland with BRAF V600E-mutated CNS tumors. The study participants include a 19-year-old male patient with ganglioglioma with anaplastic features, a 21-year-old male patient with CNS involvement of RDD, and a 28-year-old female patient with ganglioglioma with anaplastic features. Two patients received radiation with concurrent temozolomide before BRAF-targeted therapy. This case series describes clinical and radiological responses to BRAF-targeted therapy in BRAF V600E-mutated gliomas across multiple tumor grades and is only the second published report of response to targeted therapy in BRAF-mutated RDD. The durability of disease control with BRAF-targeted therapy was generally superior to that achieved with chemoradiation; one patient has experienced ongoing disease control for 5 years. The reported case of treatment response in BRAF-mutated RDD supports the strategy of genotyping and utilization of targeted therapy in this rare disease. The optimal sequencing of BRAF-targeted therapy in BRAF-mutated gliomas/glioneuronal tumors remains unclear, and further prospective studies are required to guide the use of genome-matched therapy in this patient population. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9813211/ /pubmed/36619621 http://dx.doi.org/10.3389/fmed.2022.1070828 Text en Copyright © 2022 Cronin, McLaughlin, Lane, Brett, Jansen, Bermingham, Wyse, Grogan, Morris and O’Reilly. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Cronin, Christopher McLaughlin, Ronan Lane, Louise Brett, Francesca M. Jansen, Michael Bermingham, Niamh Wyse, Gerald Grogan, Liam Morris, Patrick G. O’Reilly, Seamus Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease |
title | Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease |
title_full | Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease |
title_fullStr | Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease |
title_full_unstemmed | Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease |
title_short | Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease |
title_sort | case report: braf-inhibitor therapy in braf-mutated primary cns tumours including one case of braf-mutated rosai-dorfman disease |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813211/ https://www.ncbi.nlm.nih.gov/pubmed/36619621 http://dx.doi.org/10.3389/fmed.2022.1070828 |
work_keys_str_mv | AT croninchristopher casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT mclaughlinronan casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT lanelouise casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT brettfrancescam casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT jansenmichael casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT berminghamniamh casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT wysegerald casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT groganliam casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT morrispatrickg casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease AT oreillyseamus casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease |